Johann-Matthias Graf von der Schulenburg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Johann-Matthias Graf von der Schulenburg has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Svenja Litzkendorf
Center for Health Economics Research Hannover (CHERH), Leibniz University Hannover, Hannover, Germany
7 shared publications - Ana Babac
AOK Bavaria, Munich, Germany
6 shared publications - Frédéric Pauer
Centre for Quality and Management in Healthcare Medical Association of Lower Saxony Hannover Germany
6 shared publications - Holger Storf
Goethe University Frankfurt, University Medicine, Institute of Medical Informatics (IMI), Frankfurt am Main, Germany
6 shared publications - Martin Frank
Centre for Quality and Management in Healthcare Medical Association of Lower Saxony Hannover Germany
6 shared publications - Franziska Schauer
Department of Dermatology, Medical Center – University of Freiburg, Faculty of Medicine University of Freiburg Freiburg Germany
5 shared publications
Latest Publications
- Open Access
- 26 October 2026
- Published by Springer Nature in Health Economics Review
- Vol. 16 (1) , 129
Families caring for children and adolescents with rare disease: a health economic evaluation of face-to-face and online psychosocial support intervention of the randomized controlled CARE-FAM-NET study
Background: Parents caring for children with rare diseases often experience a reduced Health-Related Quality of Life (HRQoL). This study addresses the growing need for therapeutic support by evaluating two innovative forms of care: CARE-FAM (CF) and a web-based program (WEP) WEP-CARE (WC). CF is a psychodynamic-psychosocial intervention with eight sessions per family over six months, aiming to improve mental health, HRQoL, and satisfaction of all family members. WC is an online intervention leveraging cognitive-behavioral writing therapy principles to achieve the same objectives. The aim of this study was to evaluate the incremental cost per quality-adjusted life year (QALY) gained for CF, WC and their combination (CF + WC) compared with the control group (CG), on a per-parent basis, over an 18-month time horizon from the German statutory health insurance (SHI) payer perspective. Methods: Children Affected by Rare disease and Their Families – Research Network (CARE-FAM-Net) is a 2 × 2 factorial, multicenter randomized controlled study conducted across 17 psychiatric hospitals in Germany with three intervention groups (CF, WC, CF + WC) and a control group. Cost evaluations utilized claims data from seven SHI funds, reflecting the SHI payer perspective, while QALYs were calculated using the EQ-5D-3 L score at four points over an 18-month time horizon. The unit of analysis was the individual parent, therefore all costs and QALYs were estimated on a per-parent basis. The primary analysis used the intention-to-treat statutory health insurance (ITT-SHI) population. Missing data were addressed through multiple imputation by chained equations with predictive mean matching, generating 20 imputed datasets that were combined using Rubin’s rules. Within-family correlation was accounted for in the statistical analyses. Numerical incremental cost-effectiveness ratios (ICERs) were reported where appropriate, and non-parametric family-cluster bootstrapping was performed to estimate statistical uncertainty. The sensitivity analysis used a restricted population. Costs and QALYs were discounted at a rate of 3%. Results: The primary ITT-SHI analysis included 653 participants, with a mean age of 39.4 years (SD 7.2), and 396 (60.6%) were female. Unadjusted mean annual discounted costs per parent were €4476 (SE €631) for CG, €3539 (SE €755) for CF, €3970 (SE €1249) for WC and €5518 (SE €1850) for CF + WC. Unadjusted mean annual discounted QALYs per parent were 0.9144 (SE 0.0079) for CG, 0.9215 (SE 0.0097) for CF, 0.9287 (SE 0.0074) for WC and 0.9313 (SE 0.0075) for CF + WC. Based on the incremental mean costs and baseline-adjusted QALY differences, CF and WC dominated CG, whereas CF + WC had an ICER of €109,371 per QALY gained. However, none of the between-group differences in costs or baseline-adjusted QALYs were statistically significant. At a willingness-to-pay (WTP) of €50,000 per QALY, the probabilities of cost-effectiveness in pairwise comparisons with CG were 84.2% for CF, 79.9% for WC, and 43.0% for CF + WC. When all strategies were compared simultaneously, WC had the highest probability of being the most cost-effective strategy (48.2%), followed by CF (37.6%), CF + WC (10.4%) and CG (3.8%). The sensitivity analysis yielded comparable results for CF and WC, whereas CF + WC also dominated CG. Leave-one-out analyses demonstrated sensitivity to individual extreme cost observations. Conclusions: In the primary analysis, CF and WC were associated with lower mean costs and positive baseline-adjusted QALY differences relative to CG, whereas CF + WC was associated with higher mean costs and a positive baseline-adjusted QALY difference. None of the differences in costs or baseline-adjusted QALYs were statistically significant. The sensitivity analysis yielded broadly comparable findings for CF and WC, whereas results differed for CF + WC. Given the study limitations, particularly the relatively small sample size, the current evidence is insufficient to support a definitive recommendation for implementation into routine care from a health economic perspective. Trial registration: The study was registered at 18th December 2018 at the German clinical trials register (Deutsches Register Klinischer Studien, DRKS, nr: DRKS00015859).
- 26 October 2026
- Published by Springer Nature in Health Economics Review
- Vol. 16 (1) , 129
Open AccessFamilies caring for children and adolescents with rare disease: a health economic evaluation of face-to-face and online psychosocial support intervention of the randomized controlled CARE-FAM-NET study
Background: Parents caring for children with rare diseases often experience a reduced Health-Related Quality of Life (HRQoL). This study addresses the growing need for therapeutic support by evaluating two innovative forms of care: CARE-FAM (CF) and a web-based program (WEP) WEP-CARE (WC). CF is a psychodynamic-psychosocial intervention with eight sessions per family over six months, aiming to improve mental health, HRQoL, and satisfaction of all family members. WC is an online intervention leveraging cognitive-behavioral writing therapy principles to achieve the same objectives. The aim of this study was to evaluate the incremental cost per quality-adjusted life year (QALY) gained for CF, WC and their combination (CF + WC) compared with the control group (CG), on a per-parent basis, over an 18-month time horizon from the German statutory health insurance (SHI) payer perspective. Methods: Children Affected by Rare disease and Their Families – Research Network (CARE-FAM-Net) is a 2 × 2 factorial, multicenter randomized controlled study conducted across 17 psychiatric hospitals in Germany with three intervention groups (CF, WC, CF + WC) and a control group. Cost evaluations utilized claims data from seven SHI funds, reflecting the SHI payer perspective, while QALYs were calculated using the EQ-5D-3 L score at four points over an 18-month time horizon. The unit of analysis was the individual parent, therefore all costs and QALYs were estimated on a per-parent basis. The primary analysis used the intention-to-treat statutory health insurance (ITT-SHI) population. Missing data were addressed through multiple imputation by chained equations with predictive mean matching, generating 20 imputed datasets that were combined using Rubin’s rules. Within-family correlation was accounted for in the statistical analyses. Numerical incremental cost-effectiveness ratios (ICERs) were reported where appropriate, and non-parametric family-cluster bootstrapping was performed to estimate statistical uncertainty. The sensitivity analysis used a restricted population. Costs and QALYs were discounted at a rate of 3%. Results: The primary ITT-SHI analysis included 653 participants, with a mean age of 39.4 years (SD 7.2), and 396 (60.6%) were female. Unadjusted mean annual discounted costs per parent were €4476 (SE €631) for CG, €3539 (SE €755) for CF, €3970 (SE €1249) for WC and €5518 (SE €1850) for CF + WC. Unadjusted mean annual discounted QALYs per parent were 0.9144 (SE 0.0079) for CG, 0.9215 (SE 0.0097) for CF, 0.9287 (SE 0.0074) for WC and 0.9313 (SE 0.0075) for CF + WC. Based on the incremental mean costs and baseline-adjusted QALY differences, CF and WC dominated CG, whereas CF + WC had an ICER of €109,371 per QALY gained. However, none of the between-group differences in costs or baseline-adjusted QALYs were statistically significant. At a willingness-to-pay (WTP) of €50,000 per QALY, the probabilities of cost-effectiveness in pairwise comparisons with CG were 84.2% for CF, 79.9% for WC, and 43.0% for CF + WC. When all strategies were compared simultaneously, WC had the highest probability of being the most cost-effective strategy (48.2%), followed by CF (37.6%), CF + WC (10.4%) and CG (3.8%). The sensitivity analysis yielded comparable results for CF and WC, whereas CF + WC also dominated CG. Leave-one-out analyses demonstrated sensitivity to individual extreme cost observations. Conclusions: In the primary analysis, CF and WC were associated with lower mean costs and positive baseline-adjusted QALY differences relative to CG, whereas CF + WC was associated with higher mean costs and a positive baseline-adjusted QALY difference. None of the differences in costs or baseline-adjusted QALYs were statistically significant. The sensitivity analysis yielded broadly comparable findings for CF and WC, whereas results differed for CF + WC. Given the study limitations, particularly the relatively small sample size, the current evidence is insufficient to support a definitive recommendation for implementation into routine care from a health economic perspective. Trial registration: The study was registered at 18th December 2018 at the German clinical trials register (Deutsches Register Klinischer Studien, DRKS, nr: DRKS00015859).
- Open Access
- 19 September 2018
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 7 (9) , e11248
Metadata Correction: Conceptualization and Implementation of the Central Information Portal on Rare Diseases: Protocol for a Qualitative Study
[This corrects the article DOI: 10.2196/resprot.7425.].
- 19 September 2018
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 7 (9) , e11248
Open AccessMetadata Correction: Conceptualization and Implementation of the Central Information Portal on Rare Diseases: Protocol for a Qualitative Study
[This corrects the article DOI: 10.2196/resprot.7425.].
- Open Access
- 18 September 2018
- Published by Springer Nature in The European Journal of Health Economics
- Vol. 20 (3) , 427-438
Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare
Background Advanced therapy medicinal products (ATMPs) are beginning to reach European markets, and questions are being asked about their value for patients and how healthcare systems should pay for them. Objectives To identify and discuss potential challenges of ATMPs in view of current health technology assessment (HTA) methodology—specifically economic evaluation methods—in Europe as it relates to ATMPs, and to suggest potential solutions to these challenges. Methods An Expert Panel reviewed current HTA principles and practices in relation to the specific characteristics of ATMPs. Results Three key topics were identified and prioritised for discussion—uncertainty, discounting, and health outcomes and value. The panel discussed that evidence challenges linked to increased uncertainty may be mitigated by collection of follow-on data, use of value of information analysis, and/or outcomes-based contracts. For discount rates, an international, multi-disciplinary forum should be established to consider the economic, social and ethical implications of the choice of rate. Finally, consideration of the feasibility of assessing the value of ATMPs beyond health gain may also be key for decision-making. Conclusions ATMPs face a challenge in demonstrating their value within current HTA frameworks. Consideration of current HTA principles and practices with regards to the specific characteristics of ATMPs and continued dialogue will be key to ensuring appropriate market access. Classification code I.
- 18 September 2018
- Published by Springer Nature in The European Journal of Health Economics
- Vol. 20 (3) , 427-438
Open AccessAdvanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare
Background Advanced therapy medicinal products (ATMPs) are beginning to reach European markets, and questions are being asked about their value for patients and how healthcare systems should pay for them. Objectives To identify and discuss potential challenges of ATMPs in view of current health technology assessment (HTA) methodology—specifically economic evaluation methods—in Europe as it relates to ATMPs, and to suggest potential solutions to these challenges. Methods An Expert Panel reviewed current HTA principles and practices in relation to the specific characteristics of ATMPs. Results Three key topics were identified and prioritised for discussion—uncertainty, discounting, and health outcomes and value. The panel discussed that evidence challenges linked to increased uncertainty may be mitigated by collection of follow-on data, use of value of information analysis, and/or outcomes-based contracts. For discount rates, an international, multi-disciplinary forum should be established to consider the economic, social and ethical implications of the choice of rate. Finally, consideration of the feasibility of assessing the value of ATMPs beyond health gain may also be key for decision-making. Conclusions ATMPs face a challenge in demonstrating their value within current HTA frameworks. Consideration of current HTA principles and practices with regards to the specific characteristics of ATMPs and continued dialogue will be key to ensuring appropriate market access. Classification code I.
- Open Access
- 27 June 2018
- Published by JMIR Publications Inc. in JMIR Preprints
Metadata Correction: Conceptualization and Implementation of the Central Information Portal on Rare Diseases: Protocol for a Qualitative Study (Preprint)
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).
- 27 June 2018
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessMetadata Correction: Conceptualization and Implementation of the Central Information Portal on Rare Diseases: Protocol for a Qualitative Study (Preprint)
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).
- Open Access
- 11 May 2018
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 7 (5) , e112
Conceptualization and Implementation of the Central Information Portal on Rare Diseases: Protocol for a Qualitative Study
Background: Recently, public and political interest has focused on people living with rare diseases and their health concerns. Due to the large number of different types of rare diseases and the sizable number of patients, taking action to improve the life of those affected is gaining importance. In 2013, the federal government of Germany adopted a national action plan for rare diseases, including the call to establish a central information portal on rare diseases (Zentrales Informationsportal uber seltene Erkrankungen, ZIPSE). Objective: The objective of this study, therefore, was to conduct scientific research on how such a portal must be designed to meet the needs of patients, their families, and medical professionals, and to provide high-quality information for information seekers. Methods: We chose a 3-step procedure to develop a needs-based prototype of a central information portal. In the first step, we determined the information needs of patients with rare diseases, their relatives, and health care professionals by means of qualitative interviews and their content-analytical evaluation. On the basis of this, we developed the basic structure of the portal. In the second step, we identified quality criteria for websites on rare diseases to ensure that the information linked with ZIPSE meets the quality demands. Therefore, we gathered existing criteria catalogs and discussed them in an expert workshop. In the third step, we implemented and tested the developed prototypical information portal. Results: A portal page was configured and made accessible on the Web. The structure of ZIPSE was based on the findings from 108 qualitative interviews with patients, their relatives, and health care professionals, through which numerous information needs were identified. We placed particularly important areas of information, such as symptoms, therapy, research, and advisory services, on the start page. Moreover, we defined 13 quality criteria, referring to factors such as author information, creation date, and privacy, enabling links with high-quality information. Moreover, 19 users tested all the developed routines based on usability and comprehensibility. Subsequently, we improved the visual presentation of search results and other important search functions. Conclusions: The implemented information portal, ZIPSE, provides high-quality information on rare diseases from a central point of access. By integrating the targeted groups as well as different experts on medical information during the construction, the website can assure an improved search for information for users. ZIPSE can also serve as a model for other Web-based information systems in the field of rare diseases.
- 11 May 2018
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 7 (5) , e112
Open AccessConceptualization and Implementation of the Central Information Portal on Rare Diseases: Protocol for a Qualitative Study
Background: Recently, public and political interest has focused on people living with rare diseases and their health concerns. Due to the large number of different types of rare diseases and the sizable number of patients, taking action to improve the life of those affected is gaining importance. In 2013, the federal government of Germany adopted a national action plan for rare diseases, including the call to establish a central information portal on rare diseases (Zentrales Informationsportal uber seltene Erkrankungen, ZIPSE). Objective: The objective of this study, therefore, was to conduct scientific research on how such a portal must be designed to meet the needs of patients, their families, and medical professionals, and to provide high-quality information for information seekers. Methods: We chose a 3-step procedure to develop a needs-based prototype of a central information portal. In the first step, we determined the information needs of patients with rare diseases, their relatives, and health care professionals by means of qualitative interviews and their content-analytical evaluation. On the basis of this, we developed the basic structure of the portal. In the second step, we identified quality criteria for websites on rare diseases to ensure that the information linked with ZIPSE meets the quality demands. Therefore, we gathered existing criteria catalogs and discussed them in an expert workshop. In the third step, we implemented and tested the developed prototypical information portal. Results: A portal page was configured and made accessible on the Web. The structure of ZIPSE was based on the findings from 108 qualitative interviews with patients, their relatives, and health care professionals, through which numerous information needs were identified. We placed particularly important areas of information, such as symptoms, therapy, research, and advisory services, on the start page. Moreover, we defined 13 quality criteria, referring to factors such as author information, creation date, and privacy, enabling links with high-quality information. Moreover, 19 users tested all the developed routines based on usability and comprehensibility. Subsequently, we improved the visual presentation of search results and other important search functions. Conclusions: The implemented information portal, ZIPSE, provides high-quality information on rare diseases from a central point of access. By integrating the targeted groups as well as different experts on medical information during the construction, the website can assure an improved search for information for users. ZIPSE can also serve as a model for other Web-based information systems in the field of rare diseases.
- Open Access
- 20 November 2017
- Published by JMIR Publications Inc. in Interactive Journal of Medical Research
- Vol. 6 (2) , e23
Shaping an Effective Health Information Website on Rare Diseases Using a Group Decision-Making Tool: Inclusion of the Perspectives of Patients, Their Family Members, and Physicians
Interactive Journal of Medical Research
- 20 November 2017
- Published by JMIR Publications Inc. in Interactive Journal of Medical Research
- Vol. 6 (2) , e23
Open AccessShaping an Effective Health Information Website on Rare Diseases Using a Group Decision-Making Tool: Inclusion of the Perspectives of Patients, Their Family Members, and Physicians
Interactive Journal of Medical Research
- Open Access
- 2 February 2017
- Published by JMIR Publications Inc. in JMIR Preprints
Conceptualization and Implementation of the Central Information Portal on Rare Diseases: Protocol for a Qualitative Study (Preprint)
BACKGROUND Recently, public and political interest has focused on people living with rare diseases and their health concerns. Due to the large number of different types of rare diseases and the sizable number of patients, taking action to improve the life of those affected is gaining importance. In 2013, the federal government of Germany adopted a national action plan for rare diseases, including the call to establish a central information portal on rare diseases (Zentrales Informationsportal über seltene Erkrankungen, ZIPSE). OBJECTIVE The objective of this study, therefore, was to conduct scientific research on how such a portal must be designed to meet the needs of patients, their families, and medical professionals, and to provide high-quality information for information seekers. METHODS We chose a 3-step procedure to develop a needs-based prototype of a central information portal. In the first step, we determined the information needs of patients with rare diseases, their relatives, and health care professionals by means of qualitative interviews and their content-analytical evaluation. On the basis of this, we developed the basic structure of the portal. In the second step, we identified quality criteria for websites on rare diseases to ensure that the information linked with ZIPSE meets the quality demands. Therefore, we gathered existing criteria catalogs and discussed them in an expert workshop. In the third step, we implemented and tested the developed prototypical information portal. RESULTS A portal page was configured and made accessible on the Web. The structure of ZIPSE was based on the findings from 108 qualitative interviews with patients, their relatives, and health care professionals, through which numerous information needs were identified. We placed particularly important areas of information, such as symptoms, therapy, research, and advisory services, on the start page. Moreover, we defined 13 quality criteria, referring to factors such as author information, creation date, and privacy, enabling links with high-quality information. Moreover, 19 users tested all the developed routines based on usability and comprehensibility. Subsequently, we improved the visual presentation of search results and other important search functions. CONCLUSIONS The implemented information portal, ZIPSE, provides high-quality information on rare diseases from a central point of access. By integrating the targeted groups as well as different experts on medical information during the construction, the website can assure an improved search for information for users. ZIPSE can also serve as a model for other Web-based information systems in the field of rare diseases. REGISTERED REPORT IDENTIFIER RR1-10.2196/7425
- 2 February 2017
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessConceptualization and Implementation of the Central Information Portal on Rare Diseases: Protocol for a Qualitative Study (Preprint)
BACKGROUND Recently, public and political interest has focused on people living with rare diseases and their health concerns. Due to the large number of different types of rare diseases and the sizable number of patients, taking action to improve the life of those affected is gaining importance. In 2013, the federal government of Germany adopted a national action plan for rare diseases, including the call to establish a central information portal on rare diseases (Zentrales Informationsportal über seltene Erkrankungen, ZIPSE). OBJECTIVE The objective of this study, therefore, was to conduct scientific research on how such a portal must be designed to meet the needs of patients, their families, and medical professionals, and to provide high-quality information for information seekers. METHODS We chose a 3-step procedure to develop a needs-based prototype of a central information portal. In the first step, we determined the information needs of patients with rare diseases, their relatives, and health care professionals by means of qualitative interviews and their content-analytical evaluation. On the basis of this, we developed the basic structure of the portal. In the second step, we identified quality criteria for websites on rare diseases to ensure that the information linked with ZIPSE meets the quality demands. Therefore, we gathered existing criteria catalogs and discussed them in an expert workshop. In the third step, we implemented and tested the developed prototypical information portal. RESULTS A portal page was configured and made accessible on the Web. The structure of ZIPSE was based on the findings from 108 qualitative interviews with patients, their relatives, and health care professionals, through which numerous information needs were identified. We placed particularly important areas of information, such as symptoms, therapy, research, and advisory services, on the start page. Moreover, we defined 13 quality criteria, referring to factors such as author information, creation date, and privacy, enabling links with high-quality information. Moreover, 19 users tested all the developed routines based on usability and comprehensibility. Subsequently, we improved the visual presentation of search results and other important search functions. CONCLUSIONS The implemented information portal, ZIPSE, provides high-quality information on rare diseases from a central point of access. By integrating the targeted groups as well as different experts on medical information during the construction, the website can assure an improved search for information for users. ZIPSE can also serve as a model for other Web-based information systems in the field of rare diseases. REGISTERED REPORT IDENTIFIER RR1-10.2196/7425
- Open Access
- 18 January 2017
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 19 (1) , e23
Rare Diseases on the Internet: An Assessment of the Quality of Online Information
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet
- 18 January 2017
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 19 (1) , e23
Open AccessRare Diseases on the Internet: An Assessment of the Quality of Online Information
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet
- Open Access
- 25 August 2016
- Published by JMIR Publications Inc. in Interactive Journal of Medical Research
- Vol. 5 (3) , e24
Adopting Quality Criteria for Websites Providing Medical Information About Rare Diseases
Interactive Journal of Medical Research
- 25 August 2016
- Published by JMIR Publications Inc. in Interactive Journal of Medical Research
- Vol. 5 (3) , e24
Open AccessAdopting Quality Criteria for Websites Providing Medical Information About Rare Diseases
Interactive Journal of Medical Research
- 1 June 2014
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 13, S119
280 VEMSE-CF: psychosocial characteristics of patients participating in a prospective controlled care research study
- 1 June 2014
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 13, S119
280 VEMSE-CF: psychosocial characteristics of patients participating in a prospective controlled care research study